MedTrace Logo

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

NCT01367236 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-10-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period.

The study will compare anti-HIV therapy combinations which are currently in use.

The patients will not have had any previous treatment for their HIV infection.

Conditions

  • HIV
  • Impaired Cognition

Interventions

DRUG

standard care

* atazanavir 300 mg daily * ritonavir 100 mg daily * tenofovir 245 mg daily\* * emtricitabine 200 mg daily\*

DRUG

novel treatment

* darunavir 800 mg daily * ritonavir 100 mg daily * lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\* * maraviroc 150 mg once daily

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Alan Winston · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01367236 on ClinicalTrials.gov